Syngene International Limited
SBI Mutual Fund entered Syngene International Limited with a new 1.95% stake, acquiring 78,78,170 shares worth approximately ₹273.68 Cr.
India's first Contract Research Organization, Syngene provides integrated drug discovery, development, and manufacturing services through a single platform known as CRAMS. Established in 1993 as a Biocon subsidiary, the company operates extensive research and manufacturing facilities spanning multiple locations across the country. It serves global pharmaceutical and biotechnology clients with end-to-end solutions, from early-stage research through commercial-scale production.
India's largest AMC by total AUM, managing over Rs 11 lakh crore across equity, debt and hybrid schemes. Backed by State Bank of India, the country's largest bank, which gives it unmatched retail reach across every Indian state. With over 70 schemes and 50 million folios, SBI MF's positioning moves are tracked as a proxy for domestic institutional flows.